Archimedes Pharma has confirmed the location of its new US headquarters in Bedminster, New Jersey.
The opening of the company’s US office marks the continued expansion of the company’s global commercial presence.
Archimedes Pharma, an emerging specialty pharma company focused on oncology, pain, neurology and critical care sectors, has offices in a number of European countries and markets a range of therapeutics in Europe. It currently markets multiple therapeutics in the UK, France, Germany and Ireland. The company is expanding its commercial presence in Spain and the US.
The company stated that the New Jersey location will provide Archimedes Pharma access to the deep resource pool of New Jersey-based specialty pharma professionals.
The company’s lead product, PecFent, a fentanyl nasal spray for the treatment of breakthrough cancer pain, received a Positive Opinion from the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) in June this year.
A New Drug Application (NDA) for the drug was submitted to the US Food and Drug Administration (FDA) in August 2009; discussions with the FDA are ongoing.
PecFent is an aqueous fentanyl citrate solution utilising Archimedes Pharma’s proprietary PecSys technology. The PecFent solution has a low viscosity and is delivered in a low volume of 100mcl using a nasal spray pump.
The PecSys technology, according to the company, avoids problems associated with simple solutions used in nasal sprays, such as dripping or swallowing of the drug solution.
New Jobs
The move will pave for new pharmaceutical jobs. The New Jersey Economic Development Authority awarded a Business Employment Incentive Programme (BEIP) grant for Archimedes Pharma US to create up to 75 new jobs.
The company will add a significant number of positions this year, including sales & marketing, regulatory, finance, human resources and medical affairs.
“With Archimedes Pharma’s rapidly growing and diverse drug delivery technologies and products portfolio, we are in the process of establishing our own US organisation and are actively recruiting top-tier senior-level management positions to support market penetration across the USA and globally. The BEIP grant awarded to us by the state was the deciding factor when choosing a US location,” said Jeffrey H. Buchalter, president and CEO of Archimedes Pharma.
Related posts: